Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (SHA:603811)
China
· Delayed Price · Currency is CNY 9.12
+0.18 (2.01%)
Jun 27, 2025, 3:00 PM CST
SHA:603811 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 213.81 | 200.7 | 162.9 | 161.58 | 170.8 | 165.14 | Upgrade
|
Depreciation & Amortization | 95.27 | 95.27 | 78.12 | 62.37 | 55.04 | 47.87 | Upgrade
|
Other Amortization | 1.58 | 1.58 | 0.67 | 0.85 | 0.79 | 0.92 | Upgrade
|
Loss (Gain) From Sale of Assets | -0.29 | -0.29 | 0 | -0.06 | 0.45 | -0 | Upgrade
|
Asset Writedown & Restructuring Costs | 24 | 24 | 7.47 | 2.82 | -7.27 | 8.12 | Upgrade
|
Loss (Gain) From Sale of Investments | -43.39 | -43.39 | -58.14 | -46.68 | -30.53 | -22.24 | Upgrade
|
Provision & Write-off of Bad Debts | -2.31 | -2.31 | 0.94 | 0.06 | 0.52 | 1.09 | Upgrade
|
Other Operating Activities | 51.06 | 16.71 | 20.54 | 18.25 | 3.91 | 11.26 | Upgrade
|
Change in Accounts Receivable | -19.24 | -19.24 | -30.46 | -63.82 | -33.47 | -42.41 | Upgrade
|
Change in Inventory | -20.83 | -20.83 | -12.03 | -3.23 | -2.11 | -27.05 | Upgrade
|
Change in Accounts Payable | 24.39 | 24.39 | 15.44 | 31.65 | -14.67 | 36.55 | Upgrade
|
Change in Other Net Operating Assets | -68.88 | -68.88 | - | - | -1.2 | - | Upgrade
|
Operating Cash Flow | 253.17 | 205.72 | 194.78 | 165.94 | 143.49 | 177.81 | Upgrade
|
Operating Cash Flow Growth | 62.75% | 5.61% | 17.38% | 15.65% | -19.30% | -1.77% | Upgrade
|
Capital Expenditures | -37.21 | -59.89 | -70.85 | -252.85 | -134.11 | -143.67 | Upgrade
|
Sale of Property, Plant & Equipment | 77.16 | 77.1 | 0 | 0.22 | 0.42 | 0.14 | Upgrade
|
Cash Acquisitions | - | - | - | - | -2.26 | - | Upgrade
|
Divestitures | -0.03 | -0.03 | - | - | - | - | Upgrade
|
Investment in Securities | 9 | 9 | 11.25 | - | 24.4 | -158.38 | Upgrade
|
Other Investing Activities | - | - | - | 11.25 | 13.34 | - | Upgrade
|
Investing Cash Flow | 48.92 | 26.18 | -59.6 | -241.38 | -101.14 | -301.91 | Upgrade
|
Long-Term Debt Issued | - | 177.8 | 295.2 | 562.13 | 92.46 | 310.31 | Upgrade
|
Total Debt Issued | 165.8 | 177.8 | 295.2 | 562.13 | 92.46 | 310.31 | Upgrade
|
Short-Term Debt Repaid | - | - | - | - | -1.48 | -4.3 | Upgrade
|
Long-Term Debt Repaid | - | -389.83 | -278.73 | -286.1 | -61.38 | -200.3 | Upgrade
|
Total Debt Repaid | -400.62 | -389.83 | -278.73 | -286.1 | -62.86 | -204.6 | Upgrade
|
Net Debt Issued (Repaid) | -234.81 | -212.02 | 16.47 | 276.03 | 29.6 | 105.71 | Upgrade
|
Repurchase of Common Stock | -67.26 | -67.26 | - | - | - | - | Upgrade
|
Common Dividends Paid | -74.59 | -76.7 | -73.95 | -68.78 | -62.87 | -52.38 | Upgrade
|
Other Financing Activities | -7.89 | - | 2.1 | - | 0.59 | 3.45 | Upgrade
|
Financing Cash Flow | -384.55 | -355.98 | -55.38 | 207.25 | -32.67 | 56.78 | Upgrade
|
Foreign Exchange Rate Adjustments | 0.08 | 0.29 | 0.03 | 0.2 | -0.54 | -0.77 | Upgrade
|
Net Cash Flow | -82.38 | -123.8 | 79.83 | 132.01 | 9.14 | -68.1 | Upgrade
|
Free Cash Flow | 215.96 | 145.83 | 123.93 | -86.92 | 9.38 | 34.13 | Upgrade
|
Free Cash Flow Growth | 165.65% | 17.67% | - | - | -72.52% | - | Upgrade
|
Free Cash Flow Margin | 28.91% | 20.41% | 18.45% | -13.27% | 1.35% | 4.50% | Upgrade
|
Free Cash Flow Per Share | 0.66 | 0.44 | 0.38 | -0.26 | 0.03 | 0.10 | Upgrade
|
Cash Interest Paid | - | - | - | - | 0.06 | 0.38 | Upgrade
|
Cash Income Tax Paid | 92.7 | 84.61 | 35.37 | 63.86 | 96.13 | 78.39 | Upgrade
|
Levered Free Cash Flow | 171.68 | 94.17 | 122.69 | -134.99 | -6.24 | -33.18 | Upgrade
|
Unlevered Free Cash Flow | 177.32 | 101.1 | 132.23 | -129.28 | -3.41 | -30.08 | Upgrade
|
Change in Net Working Capital | -30.52 | 13.01 | -48.84 | 11.73 | 21.24 | 38.06 | Upgrade
|
Updated Oct 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.